Tumor suppressor VSTM2A as a biomarker for colorectal cancer
AssigneeThe Chinese University of Hong Kong
InventorsJun Yu, Joseph Jao Yiu Sung, Simon Siu Man Ng, Yujuan Dong
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for diagnosing and determining prognosis of colorectal cancer in a subject by detecting suppressed expression of the VSTM2A gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating colorectal cancer by increasing VSTM2A gene expression or activity.
Claims10
A method for assessing risk for colorectal cancer in a human subject, comprising the steps of:
- (a) treating genomic DNA from a colorectal sample taken from the subject with a bisulfate;
- (b) performing a polymerase chain reaction (PCR) using a primer comprising nucleotide sequence of SEQ ID NO:15 or 16 to determine number of methylated CpGs in a genomic sequence, which is the 167-319 segment of SEQ ID NO:17 or a fragment thereof comprising at least 5 CpGs, and
- (c) comparing the number of methylated CpGs from step (b) with the number of methylated CpGs in the same genomic sequence, which is taken from a human non-cancer colorectal sample and has been processed through steps (a) and (b);
- and
- (d) determining the human subject, whose colorectal sample contains more methylated CpGs in the genomic sequence determined in step (b) compared to the number of methylated CpGs with the number of methylated CpGs in the same genomic sequence from a human non-cancer colorectal sample and having been processed through steps (a) and (b), as having an increased risk for colorectal cancer compared with a healthy human subject not diagnosed with colorectal cancer.
A method for assessing likelihood of mortality from colorectal cancer in a human colorectal cancer patient, comprising the steps of:
- (a) treating genomic DNA from a colorectal cancer sample taken from a first human colorectal cancer patient with a bisulfite;
- (b) performing a polymerase chain reaction (PCR) using a primer comprising nucleotide sequence of SEQ ID NO:15 or 16 to determine number of methylated CpGs in a genomic sequence, which is the 167-319 segment of SEQ ID NO:17 or a fragment thereof comprising at least 5 CpGs, and
- (c) comparing the number of methylated CpGs from step (b) with the number of methylated CpGs in the same genomic sequence, which is taken from another colorectal cancer sample of the same type obtained from a second human colorectal cancer patient and has been processed through steps (a) and (b);
- and
- (d) determining the first human patient, whose colorectal cancer sample contains more methylated CpGs in the genomic sequence determined in step (b) compared to the number of methylated CpGs with the number of methylated CpGs in the same genomic sequence taken from the colorectal cancer sample obtained from the second human patient and having been processed through steps (a) and (b), as having an increased likelihood of mortality from colorectal cancer compared with the second human colorectal cancer patient.
Dependencies are inferred from the claim text.